Purpose Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based
chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which …

Purpose To conduct a systematic review and meta-analysis of current studies to determine
whether exercise affects chemotherapy-induced peripheral neuropathy (CIPN) symptoms in …

Purpose Summarize and critically evaluate the existing studies to determine the effects of
exercise on chemotherapy-induced peripheral neuropathy in cancer patients. Methods We …

Simple Summary Chemotherapy-induced peripheral neuropathy (CIPN) is a common side
effect of cancer treatment. It is experienced as numbness, tingling, pain, and cramping in the …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is the most common
neurological and clinically relevant side effect of many commonly used chemotherapeutic …

Background No effective cures for chemotherapy-induced peripheral neuropathy (CIPN) are
known; however, exercise may be beneficial. Objective The purpose of this review was to …

Purpose Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 40% of cancer
survivors and is associated with functional deficits and an increased falls incidence. There …

Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect
of taxane treatment and cannot currently be prevented or adequately treated. Physical …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication after
chemotherapy that can damage the sensory, motor, autonomic, or cranial nerves in …

Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common
toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and …